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Presently, orthotopic liver transplant is the major therapeutic option for patients affected by primary liver 
diseases. This procedure is characterized by major invasive surgery, scarcity of donor organs, high costs, and 
lifelong immunosuppressive treatment. Transplant of hepatic precursor cells represents an attractive alterna-
tive. These cells could be used either for allogeneic transplantation or for autologous transplant after ex vivo 
genetic modification. We used stromal cells isolated from adipose tissue (AT-SCs) as platforms for autolo-
gous cell-mediated gene therapy. AT-SCs were transduced with lentiviral vectors expressing firefly luciferase, 
allowing for transplanted cell tracking by bioluminescent imaging (BLI). As a complementary approach, we 
followed circulating human a1-antitrypsin (hAAT) levels after infusion of AT-SCs overexpressing hAAT. Cells 
were transplanted into syngeneic mice after CCl4-induced hepatic injury. Luciferase bioluminescence signals 
and serum hAAT levels were measured at different time points after transplantation and demonstrate persist-
ence of transplanted cells for up to 2 months after administration. These data, along with immunohistochemical 
analysis, suggest engraftment and repopulation of injured livers by transplanted AT-SCs. Moreover, by tran-
scriptional targeting using cellular tissue-specific regulatory sequences, we confirmed that AT-SCs differenti-
ate towards a hepatogenic-like phenotype in vitro and in vivo. Additionally, in transplanted cells reisolated 
from recipient animals’ livers, we detected activation of the a-fetoprotein (AFP) promoter. This promoter is 
normally transcriptionally silenced in adult tissues but can be reactivated during liver regeneration, suggest-
ing commitment towards hepatogenic-like differentiation of engrafted cells in vivo. Our data support AT-SC-
mediated gene therapy as an innovative therapeutic option for disorders of liver metabolism.
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INTRODUCTION
Inherited diseases of liver metabolism, which are 
mostly caused by deficiency of hepatic proteins, together 
with chronic liver degenerating diseases, are a serious 
healthcare problem. At present, orthotopic liver transplan-
tation (OLT) represents the ultimate treatment for these 
diseases. However, clinical application of this surgical 
procedure has some limitations including organ scarcity, 
major surgical intervention, and lifelong immunosuppres-
sion, which often demonstrates complications, high costs, 
and eventual organ rejection (8). Hepatocyte transplant 
(HcTx) represents an alternative procedure to liver trans-
plantation (13). One of the main problems encountered 
in the practice of HcTx is the availability of livers for 
cell isolation. Hepatocytes are generally obtained from 
organs not considered suitable for liver transplantation, 
affecting the quality of isolated cells and limiting the pos-
sibility of their cryopreservation. Another major hurdle of 
HcTx is the short-term clinical efficacy, due to the limited 
repopulation capability of hepatocytes. This limitation 
may arise from the terminally differentiated status of the 
transplanted cells (13). Despite these problems, HcTx has 
proved to be effective in Crigler–Najjar disease (10) and 
a1-antitrypsin and ornithine transcarbamylase deficiency 
(43) even when transplanted cells make up only 1−5% of 
the total hepatocyte mass. These studies provide proof of 
principle for cell transplantation as a valuable therapeutic 
option for several inherited liver metabolic diseases.
The cell therapy approach for liver disease was aided 
by the identification of precursor cells able to differenti-
ate into hepatocytes (18,42). In rodents, both hepatocytes 
and biliary epithelia arise from rare hepatic progenitors 
1998 DI ROCCO ET AL.
(oval cells) present in the liver near the canals of Hering, 
but the precise role of such cells in liver regeneration is 
unclear (45). Furthermore, isolation and amplification of 
hepatic progenitors cells from human liver samples are 
challenging since their exact localization and expression 
of specific markers are not completely understood (33). 
However, hepatocyte-like cells have been obtained from 
cells isolated from a growing number of extra hepatic 
tissues [for review, see (18)], including adipose tissue 
(2,30,38). Clinical use of hepatic precursor cell transplant 
has been proposed as a bridge to OLT (28), performed 
on a Crigler–Najjar patient (15) and for the treatment of 
liver cirrhosis (32); however, translational research on 
this topic is incomplete (33).
Adipose tissue (AT) represents an attractive cell source 
for the development of cell therapy and cell-mediated 
gene therapy platforms (12). AT is abundant, replenish-
able, and accessible with minimal invasive procedures. 
When subjected to specific stimuli, adipose tissue-derived 
stromal cells (AT-SCs) are able to differentiate into sev-
eral cells types of both mesodermal and nonmesodermal 
origin, including hepatocytes [for review, see (34)].
In the current study, we show that genetically modi-
fied AT-SCs administered into an animal model of hepatic 
injury may engraft and repopulate injured liver with con-
comitant expression of a therapeutic transgene. By in vivo 
bioluminescent imaging (BLI), we were able to track 
administered cells and determine their biodistribution and 
persistence for up to 2 months after infusion. Transplanted 
cells predominantly engraft in regions undergoing liver 
regeneration and acquire some markers specific of a 
hepatic phenotype. In addition, transplanted cells can be 
reisolated from the liver of recipient animals. In these 
cells, we detected activation of the a-fetoprotein (AFP) 
promoter, suggesting commitment towards hepato genic 
differentiation in vivo (17).
Taken together, our data indicate that AT-SCs may 
represent a valuable supply of hepatic precursors as well 
as a suitable target for cell-mediated gene therapy for 
liver disease.
MATERIALS AND METhODS
Cell Isolation and Culture
AT-SCs were obtained from 6-week-old wild-type 
Swiss CD1 mice as previously described (6). Approx-
imately 0.8–1.2 ´  106 AT-SCs were isolated from each 
6-week-old mouse (5). Fluorescence-activated cell sort-
ing (FACS) analysis at second passage confirms the 
expression of typical adipose tissue-derived mesenchy-
mal stromal cell (AT-MSC) markers such as cluster of 
differentiation 90 (CD90) and CD54 and the absence of 
hematopoietic and endothelial markers such as CD45, 
CD34, and CD31. Human hepatocarcinoma HEP G2 
(ATCC® No. HB-8065) and human adenocarcinoma HeLa 
(ATCC® No. CCL-2) cells were cultured following ATCC 
recommendations.
In Vitro Hepatogenic Differentiation
AT-SCs were used for differentiation assays accord-
ing to a protocol originally described to induce in vitro 
a hepatic phenotype in of human bone marrow mesen-
chymal cells (20). A method to induce hepatic differ-
entiation in mesenchymal cells isolated from adipose 
tissue was subsequently described by Talens-Visconti 
et al. (44). Briefly, freshly isolated adipose tissue cells 
were plated at 2.5 ´  104 cells/cm2 on tissue culture dishes 
in a-modified minimum essential medium (a-MEM) 
supplemented with 20% fetal bovine serum (FBS), 2 mM 
l-glutamine, and 1% penicillin–streptomycin and incu-
bated overnight at 37°C and 5% CO2 (preselection step). 
Nonadherent cells were discarded, medium was replaced, 
and cells were allowed to grow until they reached 80% 
confluence (expansion step). Cells were then subcultured 
at 1:3 ratio, and starting the next day, they were serum-
deprived for 2 days in a-MEM. Cells were then cul-
tured in the same medium supplemented with 20 ng/ml 
epidermal growth factor (EGF) and 10 ng/ml basic 
fibroblast growth factor (bFGF) for 7 days (condition-
ing step). Induction of hepatic phenotype was achieved 
by sequential addition of 20 ng/ml hepatic growth 
factor (HGF), 10 ng/ml bFGF, and 4.9 mmol/L nico-
tinamide, for 7 days (differentiation step); then a-MEM 
was supplemented with 20 ng/ml oncostatin M (OMS), 
1 μmol/L dexamethasone, and 10 μl/ml insulin transfer-
rin selenium (ITS) + premix for 5 more days to achieve 
cell maturation (terminal differentiation step).
Reverse Transcription-Polymerase Chain  
Reaction (RT-PCR)
Total RNA was extracted from cells at different 
time points during the hepatic differentiation procedure 
using an RNeasy Mini Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. RNA was 
reverse-transcribed with Moloney murine leukemia virus 
(M-MLV) reverse transcriptase (Promega, Madison, WI) 
using random hexamers. Thermal cycling conditions and 
primers used for RT-PCR of liver-associated genes have 
been described elsewhere (36,39).
Lentiviral Vector Production and Titration
Lentiviral vectors (LVs) used in this study were third-
generation self-inactivating (SIN) vectors derived from 
pCCLsin.cPPT.hPGK.E-GFP.Wpre (phosphoglycerate 
kinase promoter-enhanced jellyfish green fluorescent pro-
tein) (9) obtained from E. Vigna (IRCC, Candiolo, Italy). 
We generated LVs containing the ubiquitously active PGK 
promoter followed by either firefly luciferase (fluc) cDNA 
or human a1-antitrypsin (hAAT) cDNA as replacements 
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to E-GFP cDNA. For transcriptional targeting studies, we 
generated a LV expressing a marker under the control of 
the liver-specific a-fetoprotein promoter (AFP). This vec-
tor was derived from the PGK.E-GFP plasmid by substi-
tuting the 0.5-kb human PGK promoter with the 2.1-kb 
human a-fetoprotein enhancer and promoter derived from 
pDrive AFP-hAFP (Invivogen, San Diego, CA).
Recombinant vesicular stomatitis virus-pseudotyped 
LVs were obtained as previously described (9). Titers 
of GFP-expressing LV stocks were determined by serial 
dilution on HeLa cells and flow cytometry analysis and 
were above 1 ´  108 transducing units/ml (TU/ml).
Lentiviral-Mediated Gene Transfer Into AT-SCs
Second passage cells were used for lentiviral-mediated 
gene transfer. AT-SCs were plated at 60% confluence in 
a-MEM supplemented with 20% FBS. On the next day, 
cells were transduced with 10 TU/cell of LV stocks in the 
presence of 6 μg/ml Polybrene®. After incubation at 37°C 
overnight, cells were trypsinized and subcultured at 1:3 
ratio and cultured for 2 more days. Cells were then har-
vested using trypsin/EDTA, washed in PBS, and used for 
FACS analysis and transplantation. Transduction efficiency 
was attested to be above 90% in all experiments. Infectivity 
of LVs decays logarithmically with time; the estimated 
half time of the LVs in a cell-free environment at 37°C is 
less than 10 h (51). However, to exclude any contaminat-
ing viral particles in the transplantation solution, 0.45-μm 
filtered LV-E-GFP cell supernatant was used to transduce 
HeLa cells. Neither FACS analysis nor fluorescent micros-
copy revealed any E-GFP-positive cells, excluding the 
presence of active viral particles in the samples.
AT-SCs Transplant
Eight-week-old wild-type Swiss CD1 mice were 
used in experimental groups of at least six animals. All 
experimental procedures were performed according to 
the guidelines of the Italian National Institutes of Health 
and were approved by the institutional animal care and 
use committee.
Acute hepatic injury was induced by intraperitoneal 
injection of carbon tetrachloride (CCl4; 1 ml/kg) (Sigma-
Aldrich, St. Louis, MO) dissolved in peanut oil (27). On 
the following day, genetically modified AT-SCs (2.5 ´  105 
in 100 μl PBS per mouse) were administered into the 
spleen using a 27-gauge needle, as previously described 
(29). Then the abdominal wall was sutured, and the skin 
was closed with wound clips.
Ex Vivo and In Vivo Optical Bioluminescence Imaging
Ex vivo and in vivo imaging analysis was performed 
using the IVIS® Lumina equipped with Living Image 3.1 
software (Caliper Life Sciences, Hopkinton, MA). For ex 
vivo imaging, cells were plated into clear bottomed tissue 
culture dishes and incubated in a solution of d-luciferin 
(Caliper Life Sciences) dissolved in tissue culture medium 
(150 μg/ml) before analysis. For in vivo analysis, mice 
were anesthetized with Avertin® and d-luciferin dissolved 
in PBS (150 mg/kg body weight) was administered IP 
10 min before analysis. Images were recorded between 1 
and 5 min, depending on the intensity of the biolumines-
cence emission. The same mice were analyzed at differ-
ent time points after transplant. Necropsy was performed, 
and single organs were analyzed ex vivo. Luciferase 
activity in cell and tissue homogenates was detected with 
a specific assay (Promega, Madison, WI).
Quantification of Human AAT Levels
Blood samples were obtained via retro-orbital bleed-
ing under sedation. Serum was obtained by centrifuga-
tion at 1,500 ´  g for 10 min. Serum levels of hAAT were 
determined using the human AAT ELISA Kit from Im -
mundiagnostik AG (Bensheim, Germany).
Immunohistochemistry
Immunohistochemistry was performed on 5-μm con-
secutive sections of formalin-fixed, paraffin-embedded 
tissue with antibodies against firefly luciferase (Sigma 
Aldrich) and murine GATA4 (Novus Biologicals, 
Littleton, CO).
Statistical Analysis
Data analysis and comparisons between control and 
treated groups were done with INSTAT (GraphPad, San 
Diego). The significance of differences was assessed 
with a two-tailed Student’s t test for unpaired data; sta-
tistical significance level was set at p < 0.05. Results are 
expressed as means ± SEM.
RESULTS
Transdifferentiation Potential and Gene Transfer  
Into AT-SCs
Several reports have proved that human AT-derived 
MSCs undergo in vitro differentiation towards the 
hepatogenic phenotype in the presence of selective 
inductive media (2,3,20). Our data indicate that murine 
AT-SCs derived from inguinal fat pads also have hepato-
genic transdifferentiation proprieties. Cytomorphological 
changes observed during the differentiation protocol were 
associated with temporal expression of liver-specific 
transcripts, including GATA4, AFP, albumin, cytochrome 
P450 (CYP2B), and cytokeratin-18 and -19 (CK-18 and 
CK-19) as assessed by RT-PCR analysis (Fig. 1A).
Potential activation of a hepatocyte-like expression 
profile in AT-SCs was also confirmed by liver-specific 
transcriptional targeting with a fluorescent marker. 
During embryogenesis (6–7 days of murine gesta-
tion), the AFP gene is normally expressed in visceral 
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endoderm of the yolk sac (19). At a later developmen-
tal stage, maximal expression is observed in fetal liver 
and, at significantly lower levels, in embryonic gut. 
AFP is transcriptionally silenced in adult tissues but 
can be restored during liver regeneration and in primary 
hepatic tumors (17,26). Activation of the AFP promoter 
in the liver is highly specific, being regulated by a 
small set of transcription factors including hepatocyte 
nuclear factor-1, -3, and -4 (HNF-1, HNF-3, HNF-4) 
and CCAAT/enhancer binding protein (C/EBP), which 
share a common liver-restricted tissue distribution (24). 
HNF-1 and HNF-4 are known to play a crucial role 
in the determination and maintenance of hepatocyte-
 specific differentiation (7).
We tested the susceptibility of AT-SCs to lentiviral- 
mediated gene transfer. A lentiviral vector (LV) express-
ing E-GFP under the control of the human AFP enhancer 
and promoter was generated. Specific hAFP promoter-
mediated expression of E-GFP was assessed in vitro in 
HEP G2 cells, reported to express high levels of AFP, 
while it was undetectable in AFP-negative HeLa cells 
(data not shown). The LV expressing E-GFP under 
the control of the AFP enhancer/promoter was then 
used for gene transfer into second passage AT-SCs. 
LV-treated cells were then cultured in either transdif-
ferentiation medium as described above or maintenance 
medium. Differentiation into the hepatic-like pheno-
type in AT-SCs was associated with E-GFP expression 
Figure 1. In vitro transdifferentiation potential of AT-SCs. Gene transfer into adipose tissue derived stromal cells (AT-SCs) was per-
formed using a lentiviral vector (LV) bearing an expression cassette driving enhanced green fluorescent protein (E-GFP) under the 
control of the liver-specific a-fetoprotein (hAFP) promoter. Second passage AT-SCs were induced to differentiate towards a hepato-
genic phenotype in a multistep, 3-week-long protocol. To determine whether differentiated cells show characteristic expression of a 
hepatic phenotype, expression of liver markers was determined by RT-PCR (A) in cells expanded in maintenance (M) or differentiating 
medium (D). AT-SCs cultured in maintenance medium showed a higher proliferation rate compared to AT-SCs cultured in differen-
tiating medium. Human AFP promoter-specific E-GFP expression was detectable by fluorescent microscopy analysis only in cells 
cultured in hepatogenic differentiation (D) medium (B). Scale bar: 100 μm. CYP, cytochrome p450; CK-18, cytokeratin-18.
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(Fig. 1B, right). After 10 days in differentiation medium 
(first differentiation step indicated in Materials and 
Methods section), approximately 40–50% of AT-SCs 
turn the AFP promoter on (express E-GFP), while after 
3 weeks (terminal differentiation step) the percentage 
drops to 20–30%. This is possibly due to the fact that, 
as described in the literature, AFP expression is turned 
off in some cells during the terminal differentiation 
stage. Cells maintained in a-MEM 20% FBS did not 
express E-GFP (Fig. 1B, left), indicating an activation 
of the fetal liver-specific AFP enhancer/promoter only 
in hepatic differentiation conditions.
In addition, we proved that AT-SCs after lentiviral-
 mediated gene transfer provide robust transgene expres-
sion. In particular, we generated LVs expressing enhanced 
green fluorescent protein (E-GFP), human a1-antitrypsin 
(hAAT), and firefly luciferase (fluc) under the ubiquitous 
human phosphoglycerate kinase (PGK) promoter. Upon 
lentiviral-mediated gene transfer at multiplicity of infec-
tion (MOI) of 10, we achieve up to 95% transduction, 
as assessed by E-GFP expression determined by FACS 
and fluorescent microscopy analysis (Fig. 2B). Moreover, 
after LV-mediated gene transfer of hAAT into murine 
AT-SCs, overexpression and secretion of hAAT was 
achieved (Fig. 2C).
Taken together, these data suggest that murine AT- 
SCs derived from inguinal fat pads have hepatogenic 
transdifferentiation properties in vitro in the presence of 
selective inductive media, in accordance with previous 
results (37).
Transplantation of Ex Vivo LV-Transduced AT-SCs in a 
Murine Model of Liver Injury
We next evaluated whether AT-SCs after minimal in 
vitro expansion and LV gene manipulation have the abil-
ity to engraft in an animal model of hepatic liver injury.
In order to follow the fate of transplanted cells, AT-SCs 
were transduced ex vivo with LV expressing luciferase 
under the control of the ubiquitous PGK promoter. 
Luciferase activity in transduced cells was determined 
Figure 2. Reporter expression after lentiviral-mediated gene transfer into AT-SCs. Before transplantation, AT-SCs were genetically 
modified by lentiviral-mediated gene transfer. In particular, we used lentiviral vectors expressing enhanced green fluorescent protein 
(E-GFP), human a1-antitrypsin (hAAT), or firefly luciferase (fluc) under the ubiquitous human phosphoglycerate kinase (PGK) pro-
moter. Bright field (A) and UV light (B) microphotographs of AT-SCs transduced with LV-E-GFP at multiplicity of infection (MOI) 10, 
72 h after gene transfer. FACS analysis of transduced cells indicated up to 95% GFP-positive cells. Scale bar: 100 μm. (C) Secretion 
of hAAT in the culture medium of LV-hAAT-transduced AT-SCs under the same conditions. Experiments were performed three times, 
each time in duplicate. Data are expressed as means ± SEM as indicated by error bars. (D) Ex vivo bioluminescence imaging (BLI) 
analysis of AT-SCs after fluc gene transfer. No signal was detected in mock-transduced cells (not shown). Representative example 
showing a portion of a tissue culture 96-well plate; experiment was performed in quadruplicate.
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Figure 3. Biodistribution after AT-SCs transplant. Swiss CD1 mice were treated with intraperitoneal injection of carbon tetrachloride 
(CCl4; 1 ml/kg) a day before transplantation of AT-SCs (2.5 ´  105 cells/mouse in 100 μl of saline solution). In vivo bioluminescence 
imaging was performed within 1 h after transplant. Mice were divided in four groups of four animals each. One group of animals 
received mock-transduced cells by intrasplenic administration (A, B, C). The other groups received AT-SCs transduced with LV-fluc 
by intrasplenic (D, E, F), intratail vein (G, H, I), or intraperitoneal administration (J, K, L). (A, D, G, J) In vivo imaging performed on 
a representative mouse of each group. (B, E, H, K ) Same animals after sacrifice and dissection. (C, F, I, L) BLI performed on a portion 
of dissected organs (h, heart; lu, lungs; li, liver; s, spleen). Scale bars: 1 cm.
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by enzymatic luciferase assay (data not shown) and by 
bioluminescence imaging (Fig. 2D). A positive signal 
was detected with as low as 5.0 ´  103 cells 2 days after 
LV-fluc-mediated gene transfer (Fig. 2D), and it was 
maintained at a similar level after up to 8 weeks of culture 
(data not shown).
Consistent lines of evidences have demonstrated that 
transplanted cell engraftment can be improved by differ-
ent methods of recipient liver preconditioning [reviewed 
in (50)]. We induced hepatic damage in Swiss CD1 mice 
by intraperitoneal injection of CCl4 a day before cell 
transplantation (27). Intrasplenic transplantation is a 
well-established route to deliver hepatocytes to the liver 
(29). We proved that this route is also the optimal route 
for hepatic delivery of AT-SCs. Conversely, systemic 
administration by intratail vein injection or intraperito-
neal delivery resulted in cell translocation into nonhepatic 
sites as assessed by in vivo imaging (Fig. 3), a problem 
possibly correlated with the size of the injected cells. In 
particular, in order to determine biodistribution of cells 
administered via different routes of administration, we 
performed in vivo imaging within 1 h after administra-
tion of identical doses of luciferase-expressing AT-SCs 
into mice after CCl4-mediated liver injury. The biolumi-
nescence image was overlaid on a light picture of the ani-
mal as reference for anatomical localization; moreover, 
BLI was performed after animals’ sacrifice and dissection 
and on isolated organs (Fig. 3). After intrasplenic deliv-
ery, cells were localized within the spleen and the liver 
(Fig. 3D, E, F). After systemic administration by intratail 
vein injection, all BLI signals were localized in lungs, 
indicating cell trapping within lung capillaries (Fig. 3G, 
H, I) (35). After intraperitoneal administration, AT-SCs 
were retained within the peritoneal cavity and were not 
detectable in heart, lungs, spleen, or liver (Fig. 3J, K, L).
In subsequent studies, Swiss CD1 mice were treated 
intrasplenically with AT-SCs expressing firefly luciferase 
24 h after CCl4-induced hepatic injury. In vivo imaging 
was performed at different time points beginning at day 
1 after transplant (Fig. 4). The signal decreased progres-
sively and, by approximately 3 weeks, was no longer 
detectable in the spleen by in vivo BLI in all mice (n = 8), 
Figure 4. Cell tracking and kinetic of engraftment by bioluminescence imaging of AT-SCs expressing firefly luciferase. Swiss CD1 
mice were injected intraperitoneally with CCl4 (1 ml/kg) a day before intrasplenic transplantation of AT-SCs transduced with LV-fluc (2.5 ´  105 cells/mouse). Longitudinal bioluminescence imaging of AT-SCs expressing luciferase in a representative animal (n = 8) and 
quantification of the signal intensity (expressed in photons/s/cm2/sr). All control animals administered with non-luciferase-expressing 
cells (n = 6) or with PBS only (n = 2) were negative for BLI signal at all time points (data not shown). Scale bar: 1 cm.
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suggesting that AT-SCs do not engraft into the spleen. 
Conversely, luminescence was detectable in the liver for 
up to 2 months, indicating persistence of administered 
cells at the site of hepatic injury.
The same animals were monitored at different time 
points after cell administration to longitudinally track and 
quantify cell engraftment. Luminescence decreased dra-
matically during the first few days after transplantation, 
possibly due to the rigors of the transplanted cells’ new 
microenvironment. Up to 90% of the BLI signal assessed 
in liver and spleen at 1 day was lost within the first 2 
weeks after transplant. Nonetheless, engraftment of a 
small proportion of cells was maintained up to 2 months 
after administration in more than 80% of the analyzed 
animals. The signal strength for each locus of engraftment 
was comparable throughout the analyzed period (Fig. 4). 
Bioluminescence at 2 months was approximately 1% of 
the signal assessed 1 day after transplant.
Upon sacrifice, livers were dissected and analyzed by 
the IVIS® Lumina imaging system and by immunohis-
tochemistry (Fig. 5). The presence of luciferase-positive 
cells was detected by BLI in several regions of the liver of 
animals transplanted with luciferase-expressing AT-SCs 
(Fig. 5E) and not in mock-treated controls (Fig. 5A). 
Immunohistochemical analysis on liver sections of trans-
planted mice confirmed the presence of luciferase posi-
tive cells whose morphology resembles that of hepatic 
cells (Fig. 5H). No fluorescent staining could be observed 
with the anti-luc antibody around the regenerating region 
in the uninjected controls (Fig. 5D).
GATA transcription factors are a conserved fam-
ily of zinc finger-containing proteins that participate 
in the specification and differentiation of multiple cell 
types during development. In particular, GATA4 plays a 
pivotal role in controlling the earliest stages of hepatic 
development (40). GATA4 is highly expressed in hepa-
tocytes and endothelial cells during early development, 
whereas GATA4 expression in the adult liver is low 
and restricted to epithelial cells surrounding the biliary 
ducts (48). However, GATA4 is reexpressed in regen-
erating liver (25). LV-transduced, luciferase-expressing 
AT-SCs (Fig. 5H) overlapped with GATA4 expression 
as assessed by immunohistochemical analysis on liver 
sections (Fig. 5G). This indicates that transplanted cells 
predominantly colocalize with regions of active hepatic 
regeneration following CCl4-induced injury. Moreover, 
GATA expression observed in luciferase-positive cells 
indicates that transplanted cells adopt a hepatic-like phe-
notype and participate in tissue regeneration.
In order to determine whether the rate of engraftment can 
support prolonged expression and secretion into the blood-
stream of a transgene with potential therapeutic index, we 
genetically modified AT-SCs to overexpress human AAT. 
AT-SCs transduced either with a mock LV or an hAAT-
expressing LV vector were administered into the spleen, as 
described above. Blood samples were obtained at different 
Figure 5. Engraftment of AT-SCs expressing firefly luciferase at the site of liver injury at 2 weeks postadministration. (A, B, C, D) An 
animal subjected to CCl4-mediated injury but without cell transplantation. (E, F, G, H) A mouse receiving CCl4-mediated injury and 
intrasplenic transplantation of luciferase expressing AT-SCs. Ex vivo imaging of dissected liver from a representative mouse of each 
group (A, E), denoting the presence of luciferase-positive cells in transplanted animals only. Images show dissected organs placed in a 
well of a six-well tissue culture plate. (B) Immunohistochemistry on consecutive liver sections using antibodies against either GATA4 
(red) or firefly luciferase (green). Nuclei are visualized by Hoechst dye (blue). Scale bars: 100 μm.
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time points after transplant. Plasma levels of human AAT 
were measured as a correlate of AT-SC engraftment after 
hepatic injury (14). Levels of hAAT were undetectable 
in all animals before transplant and in animals undergo-
ing transplantation with mock-transduced cells. On the 
other hand, hAAT was detectable in mice receiving intras-
plenic administration of AT-SCs genetically modified with 
LV-hAAT up to 7 weeks after transplantation (Fig. 6).
These data provide evidence that the amount of 
engrafted AT-SCs is sufficient to secrete detectable levels 
of protein for almost 2 months.
Activation of AFP Promoter in Transplanted Cells 
Reisolated From Injected Livers
AFP is a suitable marker for hepatic differentiation since 
it is expressed during fetal liver development and regenera-
tion but not in healthy adult tissue (17). AT-SCs express-
ing luciferase were transduced with LVs expressing GFP 
under the control of the specific AFP promoter (LV-AFPPr.
EGFP). Cells were then transplanted as described before, 
and animals were sacrificed 10 days later. Site of trans-
planted cell engraftment were detected by BLI; correspond-
ing regions were dissected, disaggregated by collagenase 
digestion, and harvested for cell culture. GPF-positive 
cells were detected by fluorescent microscopy in cultures 
of cells isolated from animals transplanted with LV-AFPPr.
EGFP-transduced AT-SCs, indicating an activation of the 
fetal liver-specific AFP enhancer/promoter at the site of 
liver engraftment (Fig. 7).
These data suggest that physiological environmental 
cues present at the site of engraftment in the injured liver 
are sufficient to promote GFP expression in engrafted 
cells under the control of the AFP promoter, which indi-
cates differentiation into hepatocyte-like cells.
DISCUSSION
Liver stem or precursor cells are emerging as promis-
ing therapeutic tools (23,42). Recently, a Crigler–Najjar 
patient was treated by infusion of hepatic progenitor cells 
isolated from fetal liver (15); moreover, several patients 
affected by liver cirrhosis have been treated by autologous 
bone marrow cell transplant (32). Additional clinical trials 
using adipose tissue-derived stromal cells aiming at liver 
regeneration have been proposed (22). The treatment of 
liver diseases with AT-SC-derived hepatic cells may have 
considerable advantages over the use of cells of different 
origin (46). Adipose tissue can be obtained with a simple, 
minimally invasive, and repeatable procedure. A clinically 
relevant number of cells can be harvested, reducing the need 
Figure 6. Serum hAAT levels in mice after intrasplenic trans-
plant of AT-SCs overexpressing hAAT. Swiss CD1 mice were 
treated with intraperitoneal injection of CCl4 (1 ml/kg) a day 
before intrasplenic transplantation of AT-SCs transduced either 
with LV-E-GFP (AT-SCs Mock) or LV-hAAT (AT-SCs hAAT) 
(2.5 ´  105 cells in 100 μl saline solution per mouse). Blood was 
drawn at multiple time points, and serum hAAT levels were quan-
tified by ELISA. The dotted line indicates ELISA limit of detec-
tion (0.4 ng/ml). Tx indicates the day of transplantation. Results 
are means ± SEM of six animals per group. All p values between 
AT-SCs hAAT-treated animals compared to AT-SCs mock mice 
were p < 0.005.
Figure 7. In vivo differentiation of AT-SCs tagged with an AFP 
promoter-driven reporter. AT-SCs were transduced ex vivo with 
lentiviral vectors driving E-GFP expression under the control 
of the liver-specific a-fetoprotein promoter (AFPPr.EGFP). 
The hAFP promoter is inactive in undifferentiated AT-SCs (see 
Fig. 1). Cells were then transplanted by intrasplenic injection in 
syngeneic animals. Ten days later, livers were dissected, hepatic 
cells were isolated and cultured, and GFP-positive cells were 
visualized under a fluorescent microscopy. Scale bar: 100 μm.
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for ex vivo cell expansion in GMP conditions, and further 
avoiding genomic instability and the difficulty in maintain-
ing undifferentiated pluripotent cells. Nevertheless, for the 
treatment of liver genetic disorders, these cells would be 
obtained from a different donor, necessitating immunosup-
pressive treatment and its associated morbidity.
Ex vivo gene delivery into progenitor cells followed 
by autologous transplant may provide for the treatment of 
different metabolic disorders currently lacking adequate 
therapeutic options. Nonetheless, many issues are unclear, 
including the specific contribution of transplanted cells to 
physiologic tissue regeneration and the biodistribution of 
cells upon administration.
Recently Aurich et al. (1) described that in vitro hepato-
genic predifferentiation of human AT-SCs facilitates 
functional hepatic integration in vivo. Our data show that 
murine AT-SCs are susceptible to ex vivo hepatic induc-
tion similarly to human cells. However, all inductive media 
formulations used for hepatogenic in vitro predifferentia-
tion (1,2,20) contain nonphysiological levels of cytok-
ines, growth factors, and hormones and therefore raise 
serious safety concerns over the suitability of this method 
for clinical trials. Moreover, most results have been pro-
duced on AT-SCs cultured in medium supplemented with 
FBS, while data on cells cultured with clinically relevant 
human serum derivatives or serum-free conditions are 
incomplete (21). Finally, the prolonged in vitro culture, 
required for efficient differentiation, is associated with 
decreased proliferation, increased cell size, and chro-
mosomal instabilities (47). Due to these limitations, we 
decided for the subsequent transplantation study to use 
cells after minimal ex vivo manipulation in noninductive 
basal medium. In this case, support for the engraftment, 
differentiation, and prolonged survival of transplanted 
cells is provided by environmental cues in the host liver. 
Our data show that endogenous signals are sufficient for 
AT-SCs to acquire hepatocyte-like characteristics, such as 
hepatocyte morphology, concomitant GATA4 expression, 
and the activation of the AFP promoter.
Different animal models of hepatic injury have been 
investigated for studying liver repopulation (11). In most 
of these models, transplanted cells have a selective advan-
tage over resident hepatocytes. For instance, Aurich et al. 
(1) used 30% partial hepatectomy and monocrotaline treat-
ment for inhibition of proliferation of resident liver cells, 
allowing transplanted cells to repopulate the organ (49). 
However, monocrotaline treatment is not clinically trans-
latable. In our study, we assessed AT-SCs engraftment in 
the liver in the absence of any selective advantage.
Recently, near infrared fluorescence has been used 
for cell tracking after HcTx in a rat experimental model 
(16). BLI involves the detection of photons from cells 
expressing a luciferase enzyme. This procedure offers 
various advantages over alternative fluorescence-based 
molecular imaging techniques, including a high signal 
to background ratio allowing for more sensitive, longitu-
dinal, and quantitative analysis (5,31) also into the liver 
(4). The intensity of the signal detected by BLI can be 
precisely quantified and correlates with the presence of 
luciferase-expressing cells and therefore with effective 
cell engraftment after administration. Since luciferin 
metabolism requires ATP to generate light, only living 
cells expressing luciferase are able to produce a signal 
(31). The possibility to perform repeated analysis on the 
same animal at different time points allowed us to follow 
the fate of AT-SCs after transplantation into CCl4-injured 
mice. In particular, we demonstrated that AT-SCs are 
capable of migrating through the spleen, engrafting in the 
liver into regenerating sites, and persisting in the hepatic 
parenchyma for up to 2 months. This is, to our knowl-
edge, the first description of the use of BLI to monitor an 
experimental approach of cell therapy for liver disorders 
using adipose tissue-derived stromal cells.
In this study, we concomitantly evaluated a cell 
therapy and a cell-mediated gene therapy approach as 
possible treatments for hepatic disorders. We show that 
AT-SCs are prone to ex vivo genetic manipulation by 
lentiviral-mediated gene transfer without affecting their 
differentiation capacity. Therefore, such cells could be 
used either for allogeneic transplantation or for autol-
ogous transplant after ex vivo genetic modification to 
promote expression of a therapeutic transgene, consid-
erably reducing the risks associated with systemic viral 
exposure. The possibility to manipulate and transplant 
autologous cells eliminates the need for lifelong immu-
nosuppression. Of note, it has been demonstrated that 
some immunosuppression treatments, applied towards 
human cell transplantation in rodents and for heter-
ologous hepatocyte transplantation, have a detrimental 
effect on the engraftment and proliferation of implanted 
hepatocytes (41).
Hepatocytes transplanted by the intrasplenic route 
reconstitute 1−5% of the host hepatocyte mass (29). 
Hepatic reconstitution to this extent may be sufficiently 
therapeutic for metabolic disorders requiring proteins in 
small amounts, such as hemophilia. After transplantation 
of hAAT-expressing AT-SCs, we observed clearly detect-
able but subphysiological levels of circulating hAAT. In 
such cases, strategies to increase transgene expression 
and/or cell engraftment are needed. Nevertheless, we pro-
vide proof of concept for secretion of a soluble factor by 
genetically engineered, engrafted AT-SCs.
In conclusion, our study shows that AT-SC-based cell 
therapy may represent an attractive clinical option for 
the treatment of both degenerative and metabolic liver 
diseases. AT-SCs can acquire hepatic-like characteris-
tics both in vitro and in vivo, and genetically modified 
AT-SCs can engraft into the regenerating liver, providing 
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durable transgene expression in the absence of any selec-
tive advantage. This validates the prospective use of 
AT-SCs as a platform for autologous cell-mediated gene 
delivery in hepatic regeneration.
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